NYSEHealth CareHealth Care ServicesS&P SmallCap 600
$42.22
+0.07 (+0.17%)
Close of Nov 06, 2026 · end-of-day data
CON 8-K filings in 2026
Every material Form 8-K Concentra Group Holdings Parent filed with the SEC in 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Concentra Group Holdings Parent, Inc. reported its third quarter 2026 financial results, highlighting an 8.6% increase in revenue to $622.1 million and a 36.0% increase in net income to $67.8 million compared to the same period in 2025. Driven by this performance, the company raised its full-year 2026 financial guidance, declared a cash dividend of $0.0625 per share, and authorized a new $250 million share repurchase program.
Revenue for the third quarter of 2026 reached $622.1 million, up 8.6% year over year.
Net income for the quarter rose 36.0% to $67.8 million, with basic and diluted earnings per share at $0.52.
The board of directors declared a cash dividend of $0.0625 per share, payable on or about December 4, 2026.
A new share repurchase program was authorized to buy back up to $250 million of outstanding common stock.
Concentra Group Holdings Parent, Inc. (NYSE: CON) said Tanner Newton, its senior vice president of strategy and finance, will become executive vice president and chief financial officer effective November 1, 2026. The change is part of a previously announced leadership succession in which Matthew DiCanio becomes president and chief executive officer and Keith Newton becomes executive chairman on the same date. The filing does not report financial results, and the terms of Tanner Newton's employment agreement will be disclosed in a later filing.
Tanner Newton, 34, was appointed EVP and CFO, effective November 1, 2026; he has been SVP of strategy and finance since January 2025.
Matthew DiCanio, currently president and CFO, becomes president and CEO on November 1, 2026; Keith Newton moves from CEO to executive chairman.
Tanner Newton is the son of Keith Newton, a board member and the current CEO; the company says no arrangements exist under which he was appointed.
Compensation terms are not yet disclosed; the company expects to file an 8-K after the employment agreement is signed.
Concentra Group Holdings Parent agreed on August 21, 2026 to buy 1,000,000 shares of its common stock from chairman Robert A. Ortenzio and related entities in a privately negotiated deal, closing August 24, 2026. The purchase, funded with cash on hand and approved by the independent Audit and Compliance Committee, represents about 0.784% of shares outstanding and reduces the share count shareholders own a stake in.
1,000,000 shares purchased at $34.65 per share, for a total of $34.65 million
Price is a 1% discount to the August 21, 2026 closing price
Transaction closed August 24, 2026; funded through cash on hand
Stockholders said the sale is to diversify their investment portfolios for financial planning purposes
Concentra reported second-quarter 2026 revenue of $606.0 million, up 10.0%, and net income attributable to the Company of $65.3 million, up 46.5%, and raised its full-year 2026 guidance. The company also said Keith Newton will step down as CEO and become executive chairman, and President and CFO Matt DiCanio will become CEO, both effective Nov. 1, 2026. The higher profit and raised outlook are the main points for shareholders, while the leadership change is a planned succession.
Q2 2026 revenue of $606.0 million, up 10.0% from $550.8 million; EPS of $0.51 versus $0.35 a year earlier
Full-year 2026 revenue guidance raised to $2.325 billion to $2.375 billion; Adjusted EBITDA guidance of $485 million to $495 million
Matt DiCanio to succeed Keith Newton as president and CEO effective Nov. 1, 2026; Robert Ortenzio to step down as board chair
Quarterly cash dividend of $0.0625 per share, payable on or about Aug. 28, 2026, to holders of record on Aug. 20, 2026
Concentra's Chief Medical Officer, Dr. John R. Anderson, is retiring effective December 31, 2026, as previously disclosed. The company has now signed a consulting agreement with him, effective January 1, 2027, running through December 31, 2027, for up to 10 hours per week at $216.00 per hour.
Dr. John R. Anderson retires as Executive Vice President and Chief Medical Officer effective December 31, 2026; he first notified the company on April 10, 2026.
Consulting agreement dated July 6, 2026, takes effect January 1, 2027, and runs through December 31, 2027, unless terminated earlier on 30 days' written notice.
Anderson's unvested restricted stock keeps vesting during the term; 25% of remaining unvested stock vests if he completes the full term.
Concentra Group Holdings Parent reported first-quarter 2026 revenue of $569.6 million, up 13.7%, and net income of $52.3 million, up 28.7%, with earnings per share of $0.39 versus $0.30 a year earlier. The company raised its full-year 2026 guidance and declared a $0.0625 per share cash dividend, while repurchasing $15.0 million of its shares in the quarter. The filing does not state the prior guidance, so the size of the raise cannot be measured from it.
Net income of $52.3 million, up 28.7% from $40.6 million; earnings per share of $0.39 versus $0.30
Adjusted EBITDA of $120.7 million, up 17.6% from $102.7 million; free cash flow of $9.9 million versus negative $4.0 million
Raised 2026 outlook: revenue of $2.275 billion to $2.375 billion; Adjusted EBITDA of $460 million to $480 million; free cash flow of $215 million to $235 million
Cash dividend of $0.0625 per share, payable June 9, 2026, to holders of record on May 19, 2026
Concentra Group Holdings Parent, Inc. said Executive Vice President and Chief Medical Officer Dr. John Anderson will retire effective December 31, 2026. The company has started a formal search for his successor and expects to enter a consulting agreement with him to support the transition. The filing includes no financial results or guidance.
Dr. John Anderson notified the company of his retirement on April 10, 2026, effective December 31, 2026.
The company has initiated a formal search for Anderson's successor.
The company expects to enter a Consulting Agreement with Anderson to support the transition of his responsibilities.
Anderson joined Concentra in 1993 and has served as Chief Medical Officer since 2014.
Concentra reported fourth-quarter 2025 revenue of $539.1 million, up 15.9%, and net income attributable to the Company of $34.7 million, up 61.2%. For full-year 2025, revenue rose 13.9% to $2,163.4 million, while net income attributable to the Company was flat at $166.4 million and EPS fell to $1.30 from $1.46. The company also gave 2026 guidance of $2.25 billion to $2.35 billion in revenue and declared a $0.0625 per share dividend.
Q4 2025 EPS was $0.27 versus $0.17 in Q4 2024; Adjusted EBITDA was $95.3 million, up 22.9%.
Full-year 2025 EPS was $1.30 versus $1.46 in 2024; full-year net income attributable to the Company was $166.4 million, down 0.1%.
2026 guidance: revenue of $2.25 billion to $2.35 billion and Adjusted EBITDA of $450 million to $470 million.
Board declared a $0.0625 per share dividend, payable on or about March 19, 2026, to holders of record on March 12, 2026.
Concentra Group Holdings released preliminary, unaudited fourth-quarter and full-year 2025 results that it says exceed its earlier full-year 2025 guidance, and it issued 2026 guidance calling for revenue of $2.25 billion to $2.35 billion. Full-year 2025 earnings per share fell to $1.30 from $1.46 a year earlier, while the company's final results are due February 26, 2026.
Full-year 2025 revenue of $2,163.4 million, up 13.9% from $1,900.2 million in 2024
Full-year 2025 earnings per share of $1.30, versus $1.46 in 2024; fourth-quarter earnings per share of $0.27, versus $0.17 in Q4 2024
2026 guidance: Adjusted EBITDA of $450 million to $470 million and free cash flow of $200 million to $225 million
Final fourth-quarter and full-year 2025 results are scheduled for February 26, 2026, with a conference call on February 27, 2026
Concentra published a presentation for the J.P. Morgan Healthcare Conference, to be given January 14, 2026, with preliminary, unaudited Q4 2025 operational metrics. The filing shows early visits-per-day growth but no revenue, profit or earnings per share figures for the quarter, which the company says will come in late January.
Early look shows Q4 2025 visits per day up year over year at +3.4%, +9.1%, +2.3% and +9.4% across total company (excluding Nova), workers' compensation and employer services.
Concentra repurchased about 1.1 million shares in Q4 2025.
Late January: Q4 and FY 2025 flash results and 2026 guidance; regularly scheduled Q4 earnings call in late February.
Presentation lists FY 2025 guidance of $2.145 billion to $2.160 billion in revenue and $425 million to $430 million in Adjusted EBITDA.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Concentra Group Holdings Parent filing is on SEC EDGAR ↗. 8-K briefs of other companies →